Abplatin(IV) inhibited tumor growth on a patient derived cancer model of hepatocellular carcinoma and its comparative multi-omics study with cisplatin
Open Access
- 3 June 2022
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 20 (1) , 1-14
Abstract
Background: Cisplatin, the alkylating agent of platinum(II) (Pt(II)), is the most common antitumor drug in clinic; however, it has many side effects, therefore it is higly desired to develop low toxicity platinum(IV) (Pt(IV)) drugs. Multi-omics analysis, as a powerful tool, has been frequently employed for the mechanism study of a certain therapy at the molecular level, which might be helpful for elucidating the mechanism of platinum drugs and facilitating their clinical application. Methods: Strating form cisplatin, a hydrophobic Pt(IV) prodrug (CisPt(IV)) with two hydrophobic aliphatic chains was synthesized, and further encapsulated with a drug carrier, human serum albumin (HSA), to form nanoparticles, namely AbPlatin(IV). The anticancer effect of AbPlatin(IV) was investigated in vitro and in vivo. Moreover, transcriptomics, metabolomics and lipidomics were performed to explore the mechanism of AbPlatin(IV). Results: Compared with cisplatin, Abplatin(IV) exhibited better tumor-targeting effect and greater tumor inhibition rate. Lipidomics study showed that Abplatin(IV) might induce the changes of BEL-7404 cell membrane, and cause the disorder of glycerophospholipids and sphingolipids. In addition, transcriptomics and metabolomics study showed that Abplatin(IV) significantly disturbed the purine metabolism pathway. Conclusions: This research highlighted the development of Abplatin(IV) and the use of multi-omics for the mechanism elucidation of prodrug, which is the key to the clinical translation of prodrug. GraphicalKeywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (21874142, 21635008)
- The National Key R&D Program of China (2018YFA0800900)
This publication has 48 references indexed in Scilit:
- Xanthosine administration does not affect the proportion of epithelial stem cells in bovine mammary tissue, but has a latent negative effect on cell proliferationExperimental Cell Research, 2014
- nab-Paclitaxel mechanisms of action and deliveryJournal of Controlled Release, 2013
- Impact of albumin on drug delivery — New applications on the horizonJournal of Controlled Release, 2012
- Molecular mechanisms of cisplatin resistanceOncogene, 2011
- Bioorganometallic chemistry—from teaching paradigms to medicinal applicationsChemical Society Reviews, 2008
- Regulation and Pathological Role of p53 in Cisplatin NephrotoxicityThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Transcriptional activation of caspase-6 and -7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicityCell Death & Differentiation, 2007
- Albumin-bound paclitaxel: a next-generation taxaneExpert Opinion on Pharmacotherapy, 2006
- Reductive Elimination/Oxidative Addition of Carbon−Hydrogen Bonds at Pt(IV)/Pt(II) Centers: Mechanistic Studies of the Solution Thermolyses of TpMe2Pt(CH3)2HJournal of the American Chemical Society, 2003
- Platinum Compounds: a New Class of Potent Antitumour AgentsNature, 1969